PD-1/PD-L1阻断可逆转肿瘤诱导的COVID-19疫苗反应钝化
该研究利用临床前模型发现,肿瘤抑制的COVID-19疫苗反应在PD-1/PD-L1免疫检查点阻断治疗下 largely 被逆转,且该恢复与抗肿瘤疗效无关,机制上与滤泡辅助T细胞和生发中心反应的增强相关。
要点
- 临床前模型显示PD-1/PD-L1阻断可逆转肿瘤对COVID-19疫苗反应的抑制。
- 疫苗效果恢复与抗肿瘤治疗效果无关。
- 机制涉及滤泡辅助T细胞和生发中心反应的增强。
核心结论
- PD-1/PD-L1阻断可大幅正常化癌症患者对COVID-19疫苗的应答,且与其抗肿瘤疗效无关。
研究设计与样本
- 研究采用临床前模型。
主要发现
- 肿瘤抑制的COVID-19疫苗反应在PD-1/PD-L1免疫检查点阻断治疗下 largely 被逆转。
- PD-1/PD-L1阻断导向的COVID-19疫苗效果恢复与抗肿瘤治疗结果无关。
- 恢复的COVID-19疫苗效果与PD-1/PD-L1阻断驱动的滤泡辅助T细胞和生发中心反应优势相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 vaccinations are crucial in protecting against the global pandemic. However, accumulating studies revealed the severely blunted COVID-19 vaccine effectiveness in cancer patients. The PD-1/PD-L1 immune checkpoint blockade (ICB) therapy leads to durable therapeutic responses in a subset of cancer patients and has been approved to treat a wide spectrum of cancers in the clinic. In this regard, it is pivotal to explore the potential impact of PD-1/PD-L1 ICB therapy on COVID-19 vaccine effectiveness during ongoing malignancy. In this study, using preclinical models, we found that the tumor-suppressed COVID-19 vaccine responses are largely reverted in the setting of PD-1/PD-L1 ICB therapy. We also identified that the PD-1/PD-L1 blockade-directed restoration of COVID-19 vaccine effectiveness is irrelevant to anti-tumor therapeutic outcomes. Mechanistically, the restored COVID-19 vaccine effectiveness is entwined with the PD-1/PD-L1 blockade-driven preponderance of follicular helper T cell and germinal center responses during ongoing malignancy. Thus, our findings indicate that PD-1/PD-L1 blockade will greatly normalize the responses of cancer patients to COVID-19 vaccination, while regardless of its anti-tumor efficacies on these patients.
引用
- Chen X, Lin Y, Yue S, et al. PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness. Vaccine. 2023. PMID: 37400286. doi:10.1016/j.vaccine.2023.06.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。